Standard BioTools Inc. (NASDAQ:LAB) Shares Sold by Jane Street Group LLC

Jane Street Group LLC decreased its holdings in Standard BioTools Inc. (NASDAQ:LAB) by 24.9% in the third quarter, Holdings Channel reports. The fund owned 181,814 shares of the company’s stock after selling 60,340 shares during the period. Jane Street Group LLC’s holdings in Standard BioTools were worth $351,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of LAB. Bank of New York Mellon Corp raised its holdings in Standard BioTools by 1,019.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 980,983 shares of the company’s stock valued at $1,736,000 after acquiring an additional 893,383 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Standard BioTools by 184.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 50,330 shares of the company’s stock valued at $89,000 after buying an additional 32,640 shares during the period. Principal Financial Group Inc. purchased a new stake in shares of Standard BioTools in the 2nd quarter valued at approximately $57,000. Rhumbline Advisers grew its stake in shares of Standard BioTools by 3,691.1% in the 2nd quarter. Rhumbline Advisers now owns 407,467 shares of the company’s stock valued at $721,000 after buying an additional 396,719 shares during the period. Finally, Victory Capital Management Inc. grew its stake in shares of Standard BioTools by 27.3% in the 2nd quarter. Victory Capital Management Inc. now owns 46,967 shares of the company’s stock valued at $83,000 after buying an additional 10,067 shares during the period. Institutional investors and hedge funds own 53.74% of the company’s stock.

Standard BioTools Stock Performance

NASDAQ:LAB opened at $1.75 on Thursday. The stock has a market capitalization of $651.46 million, a P/E ratio of -2.46 and a beta of 1.61. The company has a 50 day moving average price of $1.87 and a 200 day moving average price of $1.90. Standard BioTools Inc. has a fifty-two week low of $1.21 and a fifty-two week high of $3.04.

Wall Street Analysts Forecast Growth

Separately, TD Cowen dropped their price target on shares of Standard BioTools from $2.75 to $2.50 and set a “buy” rating for the company in a research note on Thursday, October 31st.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.